Estrella Immunopharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023
Net Income	-13.06	-8.85	-7.31	-11.11
Stock-Based Compensation	0.62	0.43	1.19	0.41
Other Adjustments	0.04	-	-	-
Changes in Accounts Payable	0.55	-0.07	-9.33	8.39
Changes in Accrued Expenses	9.64	2.71	-0.47	0.14
Changes in Income Taxes Payable	-0	-0.04	-0	0
Changes in Other Operating Activities	0.43	-1.82	-0.15	0.83
Operating Cash Flow	-1.79	-7.64	-16.07	-1.34
Proceeds from Sale of Investments	-	-	5.07	-
Other Investing Activities	-	-	-0.11	-0.27
Investing Cash Flow	-	-	4.96	-0.27
Short-Term Debt Issued	-	-	0.3	-
Short-Term Debt Repaid	-	-	-0.3	-
Issuance of Common Stock	2.4	0.08	10.73	-
Repurchase of Common Stock	-0.03	-0.57	-0.35	-
Net Common Stock Issued (Repurchased)	2.37	-0.49	10.37	-
Issuance of Preferred Stock	-	-	9.02	-
Net Preferred Stock Issued (Repurchased)	-	-	9.02	-
Other Financing Activities	-0.12	-	-6.6	-
Financing Cash Flow	2.25	-0.49	12.79	-
Net Cash Flow	0.47	-8.13	1.69	-1.61
Free Cash Flow	-1.79	-7.64	-16.07	-1.34
Free Cash Flow Per Share	-0.05	-0.21	-0.59	-0.94
Levered Free Cash Flow	-2.44	0.78	-17.26	-1.75
Unlevered Free Cash Flow	-2.44	0.78	-17.26	-1.75

SEC Filings: 10-K · 10-Q